Search - tctmd.com

Displaying 181 - 200 of 1102

Sort: Relevancy | Date

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

Title (ideally under 60 characters) DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

September 15, 2021

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

September 07, 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

September 02, 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Early Recurrent Events After Acute MI: Clues to Origins Hint at Solutions

News Daily News

Early Recurrent Events After Acute MI: Clues to Origins Hint at Solutions

August 10, 2021

New-Generation Watchman FLX Maintains Good Results Through 2 Years

News Conference News TVT 2021

New-Generation Watchman FLX Maintains Good Results Through 2 Years

July 28, 2021

Predictors of Device-Related Thrombus Following LAA Occlusion

News Daily News

Predictors of Device-Related Thrombus Following LAA Occlusion

July 19, 2021

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

FDA Permits 28-Day DAPT in Xience-Treated Patients at High Bleeding Risk

News Daily News

FDA Permits 28-Day DAPT in Xience-Treated Patients at High Bleeding Risk

Michael O'Riordan

June 30, 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

News Conference News EAS 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

Michael O'Riordan

June 08, 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

News Conference News ACC 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Yael L. Maxwell

May 26, 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.